Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Positive transcription elongation factor b (P-TEFb) is a multiprotein complex that plays an essential role in the regulation of gene expression by facilitating the transition of RNA polymerase II (Pol II) from promoter-proximal pausing to productive elongation during transcription in eukaryotic cells. P-TEFb consists primarily of two subunits: cyclin-dependent kinase 9 (CDK9) and a regulatory cyclin (T1, T2, or K). P-TEFb phosphorylates the CTD of RNA polymerase II and negative elongation factors, releasing Pol II from pausing. It is negatively regulated by HEXIM proteins and positively by BRD4 and the super elongation complex. P-TEFb is essential for general gene expression, plays a specific role in muscle cell development, and contributes to inflammatory diseases and cancer. HIV exploits P-TEFb for efficient replication. P-TEFb inhibitors are under investigation for cancer therapy.
CDK9 kinase inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Positive Transcription Elongation Factor b (P-TEFb).